BeyondSpring Inc. Aktie News

FLORHAM PARK, N.J., 29. Sept. 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) („BeyondSpring“ oder „das Unternehmen“), ein Unternehmen im klinischen Stadium, das innovative Therapien zur Behandlung von Krebs und anderen Erkrankungen entwickelt, gab heute bekannt, dass die U.S. Food and Drug Administration („FDA") Plinabulin zusammen mit Docetaxel den Fast-Track-Status für die Behandlu...

ASCO 2026-Daten zeigen einen langfristigen Überlebensvorteil von Plinabulin/Docetaxel und Pembrolizumab bei metastasiertem NSCLC nach Progression unter einer Erstlinien-Checkpoint-Inhibitor-(ICI)-Therapie

FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need, today announced a leadership transition designed to deliver focused, disciplined execution on BeyondSpring's most important near-term objective: completing DUBLIN...

FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced updated efficacy and safety data from the investigator-initiated Phase 2 303 Study evaluating pembrolizumab plus Plinabulin and docetaxel in patients ...

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada,...

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”)...

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy